<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740645</url>
  </required_header>
  <id_info>
    <org_study_id>000248</org_study_id>
    <nct_id>NCT04740645</nct_id>
  </id_info>
  <brief_title>NOCDURNA PASS Study Using Registries in Denmark, Germany and Sweden</brief_title>
  <official_title>Post-authorisation Safety Study of NOCDURNA for the Symptomatic Treatment of Nocturia Due to Idiopathic Nocturnal Polyuria: A Multi-country Cohort Study Using Secondary Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study using medical records to evaluate safety issues for the NOCDURNA drug using national&#xD;
      register data from Denmark and Sweden, and a health care register covering parts of Germany.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of symptomatic hyponatraemia</measure>
    <time_frame>Through study completion, typically 2 months</time_frame>
    <description>Symptomatic hyponatraemia was defined as a primary or secondary diagnosis of hyponatraemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of hyponatraemia requiring hospital intensive care</measure>
    <time_frame>Through study completion, typically 2 months</time_frame>
    <description>Hyponatraemia requiring hospital intensive care was defined as a primary or secondary diagnosis of hyponatraemia recorded in an intensive care unit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of clinically significant hyponatraemia</measure>
    <time_frame>Through study completion, typically 2 months</time_frame>
    <description>Clinically significant hyponatraemia was defined as a serum sodium concentration of &lt;130 mmol/L. Severity of hyponatraemia was categorized as mild hyponatraemia (serum sodium concentration: 130 to &lt;135 mmol/L), moderate hyponatraemia (serum sodium concentration: &gt;125 to &lt;130 mmol/L) and severe hyponatraemia (serum sodium concentration: less than equal to [â‰¤]125 mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause mortality</measure>
    <time_frame>Through study completion, typically 2 months</time_frame>
    <description>All-cause mortality was defined as death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of major adverse cardiovascular events (MACE)</measure>
    <time_frame>Through study completion, typically 2 months</time_frame>
    <description>Major adverse cardiovascular events were defined as a record of myocardial infarction and stroke. Fatal and non-fatal events will be considered separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of major venous thromboembolic events (VTEs)</measure>
    <time_frame>Through study completion, typically 2 months</time_frame>
    <description>Venous thromboembolic events were defined as a record of a deep vein thrombosis, pulmonary embolism or portal vein thrombosis. Fatal and non-fatal events will be considered separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate acute exacerbation of congestive heart failure</measure>
    <time_frame>Through study completion, typically 2 months</time_frame>
    <description>Acute exacerbation of congestive heart failure was defined as primary diagnosis of acute or acute-on-chronic heart failure from hospital inpatient care or the acute and emergency ward, or death from heart failure as the underlying or contributory cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events of MACE and VTE in Sweden</measure>
    <time_frame>Through study completion, typically 2 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300000</enrollment>
  <condition>Adverse Drug Event</condition>
  <arm_group>
    <arm_group_label>NOCDURNA cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower urinary tract symptoms (LUTS) Cohort</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NOCDURNA Cohort</intervention_name>
    <description>Non intervention</description>
    <arm_group_label>NOCDURNA cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>LUTS Cohort</intervention_name>
    <description>Non intervention</description>
    <arm_group_label>Lower urinary tract symptoms (LUTS) Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with nocturia due to idiopathic nocturnal polyuria or treatment for LUTS.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Usage of NOCDURNA recorded as dispensations from drugstores in adults or or usage of&#xD;
             drugs for LUTS.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple dispensation of NOCDURNA on the same day or treatment with vasopressin 6&#xD;
             months before study start.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Compliance</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Global Clinical Compliance</last_name>
    <phone>+1 833-548-1402 (US/Canada)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Clinical Compliance</last_name>
    <phone>+1 862-286-5200 (outside US)</phone>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>German health care register, BIPS (there may be other sites)</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nocturia</keyword>
  <keyword>NOCDURNA</keyword>
  <keyword>Post-authorisation Safety Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not possible due to GDPR and other laws.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

